OKAY
833230
CHANGFU CO.,LTD
871396
Gansu Longshenrongfa Pharmaceutical Industry
300534
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
US Stock MarketDetailed Quotes
IMAB I-Mab
- 0.824
- -0.017-2.07%
Close Mar 31 16:00 ET
67.15MMarket Cap-0.86P/E (TTM)
0.834High0.781Low142.46KVolume0.824Open0.841Pre Close114.55KTurnover0.30%Turnover RatioLossP/E (Static)81.50MShares2.00052wk High0.31P/B39.55MFloat Cap0.76052wk Low--Dividend TTM48.01MShs Float85.400Historical High--Div YieldTTM6.32%Amplitude0.760Historical Low0.804Avg Price1Lot Size
About I-Mab Company
I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zang on June 30, 2016 and is headquartered in Rockville, MD.
Company Profile
SymbolIMAB
Company NameI-Mab
Listing DateJan 17, 2020
Issue Price14.00
Founded2016
CEODr. Xi-Yong Sean Fu
MarketNASDAQ
Employees220
Securities TypeDR
ADS Ratio10.0 : 23.0
Fiscal Year Ends12-31
Address2440 Research Boulevard,Suite 400
CityRockville
ProvinceMaryland
CountryUnited States of America
Zip Code20850
Phone1-240-745-6330
Company Executives
- Name
- Position
- Salary
- Dr. Xi-Yong Sean Fu
- Chief Executive Officer and Director
- --
- Joseph Skelton
- Chief Financial Officer
- --
- Dr. Phillip Dennis, M.D.
- Chief Medical Officer
- --
- Wei Fu
- Chairman of the Board
- --
- Chun Kwok Alan Au
- Independent Director
- --
- Chia-hung Conor Yang
- Independent Director
- --
- Lielie Zhang
- Independent Director
- --
Market Insights
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings